Tadalafil History: Development, Approval and Market Evolution

Tadalafil History Timeline

Tadalafil's development is easier to understand as a sequence rather than as one approval event. The molecule moved from experimental PDE5 research into an ED medicine, then accumulated new dosing frameworks, indications, brands and generic versions over the following two decades.

The dates below focus on milestones that changed tadalafil's regulatory or product identity rather than cataloging every clinical study, patent filing or national launch.

The Story Began With PDE5 Research, Not With the Cialis Name

The chemical and pharmacologic story that eventually produced tadalafil developed from research into phosphodiesterases and compounds capable of inhibiting PDE5. Early work involved Glaxo researchers and intellectual property that later moved into the ICOS development program, where the candidate was known during development as IC351.

Historical accounts of the discovery involve multiple research steps, patent rights and collaborations, so it is more accurate to describe tadalafil as emerging from a research lineage than to reduce its discovery to a single commercial brand event. Cialis did not yet exist as the marketed identity during this stage.

ICOS Advanced the Candidate Through the 1990s

By the mid-1990s, ICOS had moved the tadalafil candidate from earlier experimental work into human clinical development. Phase I testing was followed by Phase II work in erectile dysfunction, helping establish the exposure, tolerability and efficacy information needed to justify larger trials.

This period is important because tadalafil was still a development program rather than an established medicine. The familiar clinical concepts now associated with Cialis emerged only after years of dose selection and controlled studies.

The Lilly ICOS Partnership Became Central to Cialis Development

In 1998, ICOS and Eli Lilly formed Lilly ICOS LLC as a 50/50 joint venture to develop and commercialize PDE5 inhibitors including tadalafil. ICOS contributed relevant intellectual property while the two companies shared development and commercialization responsibilities.

The partnership helped move the program into Phase III and later into worldwide commercialization. This corporate structure is an important part of tadalafil history because Cialis originally emerged from a Lilly-ICOS collaboration rather than from Lilly acting alone.

Late-Stage Development Turned the Molecule Into a Regulatory Candidate

The Phase III program began around the end of the 1990s, and company filings record a U.S. NDA filing milestone in 2001. By this stage, the program had shifted from asking whether tadalafil might work in ED to assembling the confirmatory efficacy, safety, pharmacology and manufacturing package needed for regulatory approval.

The transition from IC351 development candidate to tadalafil/Cialis regulatory product is therefore better viewed as a multiyear process. The eventual brand launch represented the endpoint of that development cycle rather than the beginning of the drug's history.

Cialis Was Authorized in the European Union Before the United States

The European regulatory milestone came first. The European Commission issued a centralized marketing authorization for Cialis on November 12, 2002, following a positive regulatory opinion earlier that year.

The original European indication centered on erectile dysfunction. This makes 2002 a useful dividing line between tadalafil as a development program and Cialis as an authorized medicine.

The 2003 U.S. Approval Established Cialis in the American ED Market

FDA approved Cialis under NDA 21-368 on November 21, 2003 for the treatment of erectile dysfunction. The original U.S. framework was as-needed treatment, establishing tadalafil as another PDE5 inhibitor option several years after sildenafil had created the modern oral ED-treatment category.

The historical importance of the approval extends beyond adding another drug to the class. Tadalafil's longer pharmacokinetic profile supported a different timing narrative from shorter-acting competitors and became closely associated with the later-response window demonstrated in clinical studies.

The detailed regulatory record is covered separately on Tadalafil FDA Approval.

Cialis Became a Billion-Dollar ED Brand by 2007

Following U.S. launch, Cialis entered an ED market that already contained sildenafil and vardenafil. Worldwide Cialis sales were approximately $746.6 million in 2005 and $971.0 million in 2006 before rising to approximately $1.216 billion in 2007, the first year annual worldwide sales exceeded $1 billion.

Commercial success is not itself evidence of superior clinical efficacy, but the sales trajectory is historically relevant because it shows how quickly tadalafil developed from a newly approved PDE5 inhibitor into a major long-term ED product.

Lilly's Acquisition of ICOS Changed the Corporate History of Tadalafil

Lilly announced an agreement to acquire ICOS in October 2006 and completed the acquisition in January 2007. The transaction ended the original independent-partner structure behind Lilly ICOS and brought the full Cialis business into Lilly.

This corporate milestone did not change tadalafil into a different drug, but it changed who controlled its continued development, marketing and commercialization. Later Cialis indications and broader tadalafil product development therefore occurred in a different ownership structure from the original launch.

Once-Daily Cialis Changed the ED Treatment Framework

Cialis initially entered the U.S. market as an as-needed ED treatment, but development continued toward regular once-daily use. Europe authorized once-daily ED treatment in 2007, and FDA approved the once-daily 2.5 mg and 5 mg ED framework in January 2008.

Historically, this mattered because tadalafil was no longer defined only by taking a tablet in anticipation of sexual activity. It acquired two different ED scheduling models, a distinction that remains part of tadalafil treatment architecture today.

The modern regimen distinction is covered on Daily vs As-Needed Tadalafil.

Tadalafil Then Expanded Beyond Erectile Dysfunction Into PAH

A major historical transition occurred when tadalafil development moved into pulmonary arterial hypertension. The European Union authorized a PAH tadalafil product in October 2008 under the name Tadalafil Lilly, while the U.S. FDA approved Adcirca for PAH on May 22, 2009.

The European PAH product was subsequently renamed Adcirca in October 2009. This created an important distinction in tadalafil's history: the same active molecule now existed within different branded and regulatory contexts for very different disease areas.

The disease-specific development is covered on Tadalafil for Pulmonary Hypertension and the drug-brand relationship on Tadalafil and Adcirca.

The 2011 BPH Approvals Broadened Cialis Beyond ED

On October 6, 2011, FDA approved once-daily Cialis for the signs and symptoms of benign prostatic hyperplasia and for men who had both ED and BPH symptoms. This was a major label expansion because Cialis was no longer solely an ED medicine in the U.S. product context.

The combined ED/BPH indication was historically notable because one tadalafil treatment framework could address two separate clinical outcome domains in the same patient. The expansion also increased the importance of distinguishing tadalafil's indications by product and regimen rather than treating the molecule as one uniform use case.

Current disease-specific context is covered on Tadalafil for BPH and Tadalafil for ED and BPH.

Generic Tadalafil Marked a New Phase in the U.S. Market

By 2018, tadalafil's U.S. history entered a generic-competition phase. FDA's first-generic records list Teva's tadalafil tablets referencing Cialis as approved on May 22, 2018, across 2.5 mg, 5 mg, 10 mg and 20 mg strengths.

The same year, Mylan received the first generic approval listed by FDA for tadalafil 20 mg tablets referencing Adcirca on August 3. The two approvals show that generic tadalafil developed along more than one reference-product pathway: ED/BPH and PAH.

Generic-drug identity and equivalence are covered separately on Generic Tadalafil.

Generic Competition Did Not Create a New Tadalafil Molecule

The arrival of generic tadalafil changed manufacturing, branding, competition and access, but not the identity of the active molecule. FDA-approved generics reference established products and must meet the applicable requirements for active ingredient, pharmaceutical equivalence, bioequivalence and manufacturing quality.

Historically, this shifted tadalafil from being recognized primarily through the Cialis and Adcirca brands toward a market in which the nonproprietary name itself became increasingly visible. The relationship between tadalafil and Cialis is explained on Tadalafil and Cialis.

Tadliq Added an Oral-Suspension Chapter to Tadalafil History

FDA approved Tadliq on June 17, 2022 as a tadalafil oral suspension for pulmonary arterial hypertension, WHO Group 1, to improve exercise ability. The product contains tadalafil 20 mg per 5 mL and expanded the U.S. PAH landscape beyond tablet-only tadalafil products.

Tadliq did not represent a new active molecule or a new ED/BPH brand. Its significance in the historical sequence is the addition of another dosage form within tadalafil's established PAH branch.

The formulation distinction is covered on Tadalafil Oral Suspension and the product itself on Tadliq.

Tadalafil's History Became a Story of One Molecule in Multiple Product Contexts

The earliest tadalafil history can be described as a single drug-development program, but the later history cannot be understood through Cialis alone. Over time the same active molecule appeared in ED/BPH products, PAH tablets, generic versions and an oral suspension.

This evolution explains why modern tadalafil terminology needs several layers: molecule, brand, dosage form, indication and treatment framework. A current map of those uses is available on Tadalafil Uses.

The Indication History Expanded in Stages

Tadalafil did not receive all of its modern use contexts at once. Erectile dysfunction came first, followed by a daily ED framework, then a separate PAH product branch, and later BPH and combined ED/BPH labeling.

The sequence matters because today's broad tadalafil entity can make the history look simpler than it was. Each expansion required its own clinical-development and regulatory evidence rather than being automatically inherited from the original ED approval.

A Later Approval Does Not Rewrite Earlier Tadalafil History

Later indication expansions should not be projected backward onto the original Cialis launch. The 2003 U.S. approval was for ED; BPH and ED/BPH arrived years later, while PAH developed through a separate product label.

Likewise, the existence of modern generic tadalafil does not mean generic products were present when Cialis first launched. A chronological page needs to preserve those regulatory stages rather than describe the present-day product landscape as though it existed from the beginning.

Drug History and FDA Approval History Are Related but Different

A history page includes discovery, development partnerships, European authorization, U.S. approval, indication expansion, corporate changes, generic competition and formulation evolution. FDA approval history is narrower and focuses on formal U.S. regulatory actions and supplemental approvals.

Keeping those intents separate prevents this page from becoming a list of NDA supplements. Readers looking specifically for U.S. regulatory dates and approval structure should use Tadalafil FDA Approval.

Common Misunderstandings About Tadalafil History

Modern familiarity with Cialis and generic tadalafil can compress a complicated development history into a few misleading assumptions. Tadalafil was not invented as a generic Cialis product, Cialis was not originally approved with every modern indication, and the PAH brand branch emerged only after the ED product was established.

The most accurate historical model is progressive expansion: experimental PDE5 inhibitor, ED drug candidate, Cialis product, additional dosing framework, PAH product, broader indications and finally a more diversified branded and generic product landscape.

Explore the Regulatory and Product History Behind Tadalafil

Tadalafil history connects several different intents: the original Cialis identity, formal U.S. approvals, PAH expansion, generic entry and the modern product landscape. The related pages below provide deeper treatment of those topics without turning this chronology into a brand catalog or regulatory database.

The history page should remain the chronological map linking those developments together.